Q1 2025 Management View Executive Chairman Bill Doyle highlighted the company’s transition to a multi-indication oncology ...

The most recent NCCN guidelines align with Flores’ take. The guidelines say that SBRT is indicated for stage IA-IIA (N0) NSCLC in patients who are deemed “medically inoperable, high surgical ...

Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Ivonescimab combined with chemotherapy showed significant progression-free survival benefits in advanced squamous NSCLC patients, including both PD-L1-positive and PD-L1-negative populations. The ...

The researchers concluded that slower turnaround time for biomarker testing is associated with early non-targeted treatment in patients with ALK +/ EGFR + advanced NSCLC, a practice that is “common,” ...

Taiwan’s health authority on Thursday said it has plans to expand existing National Health Insurance (NHI) coverage to ...

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

The NCCN Annual Conference brings together leading minds and subject matter experts in front of a multidisciplinary audience to share the latest recommendations for cancer treatment and prevention.